JP2017512801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512801A5 JP2017512801A5 JP2016559853A JP2016559853A JP2017512801A5 JP 2017512801 A5 JP2017512801 A5 JP 2017512801A5 JP 2016559853 A JP2016559853 A JP 2016559853A JP 2016559853 A JP2016559853 A JP 2016559853A JP 2017512801 A5 JP2017512801 A5 JP 2017512801A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administered
- dose
- body weight
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 11
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 10
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 10
- 230000037396 body weight Effects 0.000 claims description 10
- 239000000611 antibody drug conjugate Substances 0.000 claims description 9
- 238000012423 maintenance Methods 0.000 claims description 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229940125644 antibody drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461976790P | 2014-04-08 | 2014-04-08 | |
| US61/976,790 | 2014-04-08 | ||
| PCT/US2015/024732 WO2015157297A1 (en) | 2014-04-08 | 2015-04-07 | Optimal dosing of a cd19-antibody drug conjugate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017512801A JP2017512801A (ja) | 2017-05-25 |
| JP2017512801A5 true JP2017512801A5 (OSRAM) | 2018-04-26 |
Family
ID=54288332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559853A Pending JP2017512801A (ja) | 2014-04-08 | 2015-04-07 | Ｃｄ１９抗体薬物コンジュゲートの最適な投薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170182178A1 (OSRAM) |
| EP (1) | EP3129052B1 (OSRAM) |
| JP (1) | JP2017512801A (OSRAM) |
| KR (1) | KR20160141727A (OSRAM) |
| CN (1) | CN106170300A (OSRAM) |
| AU (1) | AU2015244004A1 (OSRAM) |
| CA (1) | CA2941154A1 (OSRAM) |
| EA (1) | EA201692016A1 (OSRAM) |
| IL (1) | IL247526A0 (OSRAM) |
| MX (1) | MX2016012258A (OSRAM) |
| SG (1) | SG11201607133QA (OSRAM) |
| WO (1) | WO2015157297A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190233522A1 (en) * | 2016-07-08 | 2019-08-01 | Genmab A/S | New dosage regimens for antibody drug conjugates based on anti-axl antibodies |
| ES2988683T3 (es) * | 2017-06-14 | 2024-11-21 | Adc Therapeutics Sa | Pautas posológicas para la administración de un CAF anti-CD19 |
| WO2019000327A1 (zh) * | 2017-06-29 | 2019-01-03 | 成都华创生物技术有限公司 | 一种trail类蛋白持续抑制肿瘤细胞生长的给药方法 |
| MY202687A (en) | 2017-12-23 | 2024-05-15 | Uwell Biopharma Inc | Pharmaceutical chimeric receptor composition and method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122018071808B8 (pt) * | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| SI2211904T1 (sl) * | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| RS56599B1 (sr) * | 2010-06-15 | 2018-02-28 | Genmab As | Konjugati humanog antitela sa lekom protiv tkivnog faktora |
| WO2012054748A2 (en) * | 2010-10-22 | 2012-04-26 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| DK2714738T3 (en) * | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
-
2015
- 2015-04-07 EP EP15775944.0A patent/EP3129052B1/en not_active Not-in-force
- 2015-04-07 KR KR1020167027123A patent/KR20160141727A/ko not_active Withdrawn
- 2015-04-07 CN CN201580019099.2A patent/CN106170300A/zh active Pending
- 2015-04-07 SG SG11201607133QA patent/SG11201607133QA/en unknown
- 2015-04-07 EA EA201692016A patent/EA201692016A1/ru unknown
- 2015-04-07 JP JP2016559853A patent/JP2017512801A/ja active Pending
- 2015-04-07 US US15/129,727 patent/US20170182178A1/en not_active Abandoned
- 2015-04-07 CA CA2941154A patent/CA2941154A1/en not_active Abandoned
- 2015-04-07 WO PCT/US2015/024732 patent/WO2015157297A1/en not_active Ceased
- 2015-04-07 AU AU2015244004A patent/AU2015244004A1/en not_active Abandoned
- 2015-04-07 MX MX2016012258A patent/MX2016012258A/es unknown
-
2016
- 2016-08-29 IL IL247526A patent/IL247526A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| CY1124532T1 (el) | Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf | |
| JP2017537905A5 (OSRAM) | ||
| JP2016530280A5 (OSRAM) | ||
| JP2018193377A5 (OSRAM) | ||
| JP2017226708A5 (OSRAM) | ||
| JP2016520082A5 (OSRAM) | ||
| JP2015007098A5 (OSRAM) | ||
| JP2016512513A5 (OSRAM) | ||
| WO2014127917A8 (en) | Combination of vaccination and inhibition of the pd-1 pathway | |
| RU2016109448A (ru) | Комбинированная терапия для лечения глиобластомы | |
| JP2015525798A5 (OSRAM) | ||
| JP2014169326A5 (OSRAM) | ||
| JP2015521607A5 (OSRAM) | ||
| JP2016515628A5 (OSRAM) | ||
| JP2021505540A5 (OSRAM) | ||
| JP2016516074A5 (OSRAM) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2017512801A5 (OSRAM) | ||
| JP2017501848A5 (OSRAM) | ||
| JP2018530578A5 (OSRAM) | ||
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| JP2018524306A5 (OSRAM) | ||
| JP2020524670A5 (OSRAM) | ||
| JP2020523384A5 (OSRAM) |